SINGAPORE, Nov. 14,
2023 /PRNewswire/ -- CytoMed Therapeutics
Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a
Singapore-based biopharmaceutical
company focused on harnessing its proprietary technologies to
develop novel donor-derived cell-based allogeneic immunotherapies
for the treatment of various cancers, today announced it will be
presenting at The Benchmark Company's 12th Annual
Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the
New York Athletic Club in New York
City.
The conference offers emerging growth and dynamic publicly
traded companies access to institutional and individual investors
in a unique one-on-one format during which CytoMed Therapeutics
will be participating in one-on-one meetings with investors and
analysts throughout the day.
To schedule a one-on-one meeting with the company, you may
submit your request online via the link provided upon registration.
To register for the conference, please visit
https://www.meetmax.com/sched/event_99181/investor_reg_new.html?attendee_role_id=INVESTOR
About The Benchmark Company
The Benchmark Company is an institutionally focused, research
driven, sales trading and investment banking firm. We were founded in 1988 and are
headquartered in New York City. Our
focus is on fostering the long-term success of our corporate
clients through raising capital, providing strategic advisory
services, generating insightful research, and developing
institutional sponsorship by leveraging the firm's sales, trading,
and equity research capabilities.
https://www.benchmarkcompany.com.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for
Science, Technology and Research (A*STAR), Singapore's leading research and development
agency in the public sector. It is a biopharmaceutical company
focused on harnessing its licensed proprietary technologies to
create novel cell-based immunotherapies for the treatment of human
cancers. The development of novel technologies has been inspired by
the clinical success of existing CAR-T therapies in treating
hematological malignancies, as well as the current clinical
limitations and commercial challenges in extrapolating the CAR-T
principle into treatment of solid tumors. For more information,
please visit www.cytomed.sg and follow us on Twitter
@CytomedSG,on LinkedIn, and Facebook
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytomed-therapeutics-to-present-at-the-benchmark-companys-upcoming-discovery-one-on-one-investor-conference-301987519.html
SOURCE CytoMed Therapeutics Limited